deltatrials
Unknown PHASE2 INTERVENTIONAL 1-arm NCT04438044

A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL

A Phase II, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Recurrent/Refractory Central Nervous System Lymphoma and Recurrent/Refractory Secondary Central Nervous System Lymphoma

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

Conditions PCNSL Secondary Central Nervous System Lymphoma
Interventions ICP-022
Updated 7 times since 2020 Last updated: Oct 10, 2022 Started: Jun 18, 2019 Primary completion: Dec 31, 2023 Completion: Dec 31, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates PCNSL and Secondary Central Nervous System Lymphoma and is currently ongoing. Beijing InnoCare Pharma Tech Co., Ltd. leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshotRecruiting~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshotRecruiting~Sep 2021 – ~Nov 2022 · 14 months · monthly snapshotRecruiting~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshotActive Not Recruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – present · 20 months · monthly snapshotUnknown

Change History

7 versions recorded

  1. Nov 2024 — Present [monthly]

    Unknown PHASE2

    Status: Active Not Recruiting → Unknown

  2. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Nov 2022 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Sep 2021 — Nov 2022 [monthly]

    Recruiting PHASE2

▶ Show 2 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  2. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    First recorded

Jun 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beijing InnoCare Pharma Tech Co., Ltd.
Data source: Beijing InnoCare Pharma Tech Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations